Formerly Access Pharmaceuticals, Inc., PlasmaTech Biopharmaceuticals, Inc.™ is a biopharmaceutical company focused on advancing targeted treatments for significant unmet patient care needs. Exploiting two distinct proprietary platforms, Salt Diafiltration (SDF™) Process and Polymer Hydrogel Technology (PHT™), PlasmaTech Bio is active in the development and commercialization of plasma-derived therapeutics and cancer supportive care products. The company has a robust product pipeline that includes two commercial stage products, MuGard® and ProctiGard™, with multiple follow-on products in development. For more information visit, www.plasmatechbio.com.